Skip to main content

Table 5 Clinical outcomes by history of use of oral contraceptives

From: Early menopause and severity of rheumatoid arthritis in women older than 45 years

  Never used (n= 67) a 1-5 years of use (n= 17) a > 5 years of use (n= 43) a
Mean age at diagnosis; years (SD) 66.2 (7.82) 58.8 (8.19) 60.1 (7.17)
Mean follow-up time; years (SD) 10.4 (3.3) 9.9 (3.1) 10.0 (3.8)
> 3 DMARDs used (%) 11/67 (16.4) 4/17 (23.5) 14/42 (33.3)
DMARDs in combination (%) 26/67 (38.8) 8/17 (47.1) 20/42 (47.6)
Biological treatment ever (%) 14/67 (20.9) 4/17 (23.5) 19/42 (45.2)
Documented radiographic erosions (ever) (%) 37/62 (59.7) 10/17 (58.8) 20/40 (50.0)
RF positive (%) 46/66 (69.7) 10/16 (62.5) 34/43 (79.1)
Mean HAQ at diagnosis (CI)b 0.75 (0.53-0.97) (n = 34) 0.93 (0.42-1.43) (n = 6) 1.06 (0.81-1.30) (n = 27)
Mean HAQ 1 year after diagnosis (CI)b 0.83 (0.61-1.05) (n = 39) 0.64 (0.20-1.09) (n = 9) 0.81 (0.56-1.06) (n = 29)
Mean HAQ 5 years after diagnosis (CI)b 0.93 (0.75-1.11) (n = 47) 0.80 (0.46-1.15) (n = 13) 0.86 (0.62-1.10) (n = 26)
Mean HAQ 10 years after diagnosis (CI)b 0.79 (0.59-1.00) (n = 33) 1.20 (0.77-1.63) (n = 7) 1.00 (0.75-1.26) (n = 21)
Cluster distribution (P = 0.56)    
   Severe RA (%) 12/47 (25.5) 3/12 (25.0) 11/25 (44.0)
   Mild/moderate seropos RA (%) 21/47 (44.7) 5/12 (41.7) 9/25 (36.0)
   Mild/moderate seroneg RA (%) 14/47 (29.8) 4/12 (33.3) 5/25 (20.0)
  1. CI, confidence interval; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SD, standard deviation. aIn case of missing data, numbers (n) indicated for each variable. bAdjusted for age at diagnosis.